{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T12:59:15Z","timestamp":1755694755552,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,1,20]],"date-time":"2018-01-20T00:00:00Z","timestamp":1516406400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s10620-018-4927-5","type":"journal-article","created":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T20:26:30Z","timestamp":1516393590000},"page":"577-582","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Refractory Heartburn: A Challenging Problem in Clinical Practice"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0431-451X","authenticated-orcid":false,"given":"Gerson","family":"Domingues","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquim Prado P.","family":"Moraes-Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronnie","family":"Fass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,20]]},"reference":[{"key":"4927_CR1","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1111\/j.1572-0241.2006.00630.x","volume":"101","author":"N Vakil van","year":"2006","unstructured":"van Vakil N, Zanten S, Kahrilas P, Dent J, Jones R. Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900\u20131920.","journal-title":"Am J Gastroenterol"},{"key":"4927_CR2","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/ajg.2012.444","volume":"108","author":"OP Katz","year":"2013","unstructured":"Katz OP, Gerson LB, Vela FM. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308\u2013328.","journal-title":"Am J Gastroenterol"},{"key":"4927_CR3","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1111\/nmo.12644","volume":"27","author":"PJ Kahrilas","year":"2015","unstructured":"Kahrilas PJ, Keefer L, Pandolfino JE. Patients with refractory reflux symptoms: what do they have and how should be managed? Neurogastroenterol Motil. 2015;27:1195\u20131201.","journal-title":"Neurogastroenterol Motil"},{"key":"4927_CR4","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1586\/17474124.2014.911660","volume":"8","author":"G Domingues","year":"2014","unstructured":"Domingues G, Moraes-Filho JPP. Noncompliance is an impact factor in the treatment of gastroesophageal reflux disease. Expert Rev Gastroenterol Hepatol. 2014;8:761\u2013765.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"4927_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/nrgastro.2016.50","volume":"13","author":"E Scarpellini","year":"2016","unstructured":"Scarpellini E, Ang D, Pauwels A, De Santis A, Vanuytsel T, Tack J. Management of refractory typical GERD symptoms. Nat Rev Gastroenterol Hepatol. 2016;13:281\u2013294.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4927_CR6","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1053\/j.gastro.2016.02.012","volume":"150","author":"Q Aziz","year":"2016","unstructured":"Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. FGIDs: esophageal disorders. Gastroenterology. 2016;150:1368\u20131379.","journal-title":"Gastroenterology"},{"key":"4927_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.5056\/jnm15151","volume":"22","author":"RM Lawenko","year":"2016","unstructured":"Lawenko RM, Lee YY. Evaluation of gastroesophageal reflux disease using the Bravo capsule pH system. J Neurogastroenterol Motil. 2016;22:25\u201330.","journal-title":"J Neurogastroenterol Motil"},{"key":"4927_CR8","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1111\/nmo.12620","volume":"27","author":"TVK Herregods","year":"2015","unstructured":"Herregods TVK, Troelstra M, Weijenborg PW, Bredenoord AJ, Smout AJPM. Patients with refractory reflux symptoms often do not have GERD. Neurogastroenterol Motil. 2015;27:1267\u20131273.","journal-title":"Neurogastroenterol Motil"},{"key":"4927_CR9","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1136\/gut.51.6.885","volume":"51","author":"R Fass","year":"2002","unstructured":"Fass R, Tougas G. Functional heartburn: the stimulus, the pain, and the brain. Gut. 2002;51:885\u2013892.","journal-title":"Gut"},{"key":"4927_CR10","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1136\/gutjnl-2016-311715","volume":"65","author":"KM Fock","year":"2016","unstructured":"Fock KM, Talley N, Goh KL, Sugano K, et al. Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an uptdate focusing on refractory reflux disease and Barrett\u00b4s oesophagus. Gut. 2016;65:1402\u20131415.","journal-title":"Gut"},{"key":"4927_CR11","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/MCG.0000000000000125","volume":"48","author":"C Maradey-Romero","year":"2014","unstructured":"Maradey-Romero C, Kale H, Fass R. Nonmedical therapeutic strategies for nonerosive reflux disease. J Clin Gastroenterol. 2014;48:584\u2013589.","journal-title":"J Clin Gastroenterol"},{"key":"4927_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1442-2050.2011.01227.x","volume":"25","author":"K Dal-Paz","year":"2012","unstructured":"Dal-Paz K, Moraes-Filho JPP, Navarro-Rodriguez T, Eisig JN, Barbuti R, Quigley EM. Low levels of adherence with proton pump inhibitor therapy contribute to therapeutic failure in gastroesophageal reflux disease. Dis Esophagus. 2012;25:107\u2013113.","journal-title":"Dis Esophagus"},{"key":"4927_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1177\/1756283X16681701","volume":"10","author":"R Fass","year":"2017","unstructured":"Fass R, Frazier R. The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease. Therap Adv Gastroenterol. 2017;10:243\u2013251.","journal-title":"Therap Adv Gastroenterol"},{"key":"4927_CR14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S0002-9343(01)00901-9","volume":"111","author":"AF Barrison","year":"2001","unstructured":"Barrison AF, Jarboe LA, Weinberg BM, Nimmagadda K, Sullivan LM, Wolfe MM. Patterns of proton pump inhibitor use in clinical practice. Am J Med. 2001;111:469\u2013473.","journal-title":"Am J Med"},{"key":"4927_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1442-2050.2011.01322.x","volume":"26","author":"T Hershcovici","year":"2013","unstructured":"Hershcovici T, Fass R. Step-by-step management of refractory gastroesophageal reflux disease. Dis Esophagus. 2013;26:27\u201336.","journal-title":"Dis Esophagus"},{"key":"4927_CR16","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1590\/S1807-59322009000800013","volume":"64","author":"JP Moraes-Filho","year":"2009","unstructured":"Moraes-Filho JP, Navarro-Rodriguez T, Eisig JN, Barbuti RC, Chinzon D, Quigley EM. Comorbidities are frequent in patients with gastroesophageal reflux disease in a tertiary health care hospital. Clinics. 2009;64:785\u2013790.","journal-title":"Clinics"},{"key":"4927_CR17","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/jgh.13233","volume":"31","author":"H Ichikawa","year":"2016","unstructured":"Ichikawa H, Sugimoto M, Sugimoto K, Andoh A, Furuta T. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis. J Gastroenterol Hepatol. 2016;31:716\u2013726.","journal-title":"J Gastroenterol Hepatol"},{"key":"4927_CR18","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1053\/gast.2001.24841","volume":"120","author":"D Sifrim","year":"2001","unstructured":"Sifrim D, Holloway R, Silny J, et al. Acid, nonacid, and gas reflux in patients with gastroesophageal disease during ambulatory 24-hour pH-impedance recordings. Gastroenterology. 2001;120:1588\u20131598.","journal-title":"Gastroenterology"},{"key":"4927_CR19","doi-asserted-by":"publisher","first-page":"13352","DOI":"10.3748\/wjg.v21.i47.13352","volume":"21","author":"K Nakagawa","year":"2015","unstructured":"Nakagawa K, Koike T, Iijima K, et al. Characteristics of symptomatic reflux episodes in japanese proton pump inhibitor-refractory non-erosive reflux disease patients. World J Gastroenterol. 2015;21:13352\u201313359.","journal-title":"World J Gastroenterol"},{"key":"4927_CR20","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/jgh.13049","volume":"31","author":"Y Xiao","year":"2016","unstructured":"Xiao Y, Liang M, Peng S, Zhang N, Chen M. Tailored therapy for the refractory GERD patients by combined multichannel intraluminal impedance-pH monitoring. J Gastroenterol Hepatol. 2016;31:350\u2013354.","journal-title":"J Gastroenterol Hepatol"},{"key":"4927_CR21","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1136\/gut.52.10.1397","volume":"52","author":"GH Koek","year":"2003","unstructured":"Koek GH, Sifrim D, Lerut T, Janssens J, Tack J. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-esophageal reflux refractory to proton pump inhibitors. Gut. 2003;52:1397\u20131402.","journal-title":"Gut"},{"key":"4927_CR22","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1053\/j.gastro.2010.04.051","volume":"139","author":"GE Boeckxstaens","year":"2010","unstructured":"Boeckxstaens GE, Beaumont H, Mertens V, et al. Effects of lesogaberan on reflux and lower esophageal sphincter functions in patients with gastroesophageal reflux disease. Gastroenterology. 2010;139:409\u2013417.","journal-title":"Gastroenterology"},{"key":"4927_CR23","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1038\/ajg.2009.718","volume":"105","author":"LB Gerson","year":"2010","unstructured":"Gerson LB, Huff FJ, Hila A, et al. Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol. 2010;105:1266\u20131275.","journal-title":"Am J Gastroenterol"},{"key":"4927_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/ncpgasthep0979","volume":"4","author":"J Richter","year":"2007","unstructured":"Richter J. How to manage refractory GERD. Nat Clin Pract Gastroenterol Hepatol. 2007;4:25.","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"4927_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3748\/wjg.14.1463","volume":"14","author":"J Molina-Infante","year":"2008","unstructured":"Molina-Infante J, Ferrando-Lamana L, Mateos-Rodriguez JM, Perez-Gallardo B, Prieto-Bermeio AB. Overlap of reflux and eosinophilic esophagitis in two patients requiring different therapies: a review of the literature. World J Gastroenterol. 2008;14:26.","journal-title":"World J Gastroenterol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-018-4927-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-4927-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-4927-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,19]],"date-time":"2019-01-19T19:38:35Z","timestamp":1547926715000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-018-4927-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,20]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["4927"],"URL":"https:\/\/doi.org\/10.1007\/s10620-018-4927-5","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"type":"print","value":"0163-2116"},{"type":"electronic","value":"1573-2568"}],"subject":[],"published":{"date-parts":[[2018,1,20]]},"assertion":[{"value":"3 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Ronnie Fass was an advisor to Ironwood, Mederi Therapeutics, Allergan, Ethicon, Horizon, speaker for AstraZeneca, Takeda, Mederi Therapeutics and Horizon, and performed research for Ironwood and Salix. The authors Gerson Domingues and Joaquim Prado P. Moraes-Filho declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}